Clover Health (CLOV) Fundamental Analysis: Revenue, Earnings & Valuation

6.06 / 10

Outperform

Fundamentally, CLOV scores 6.1/10 with strong accounts receivable turnover, fixed‑asset turnover, current ratio and interest coverage. Cash‑up and asset‑MV lag, but overall rating is Outperform, indicating solid quality.

Analysis Checks(7/10)

Revenue-MV

Value1.07

Score1/3

Weight4.36%

1M Return1.04%

Net profit attributable to parent company shareholders / Net profit (%)

Value100.00

Score3/3

Weight12.78%

1M Return2.92%

Accounts receivable turnover ratio

Value26.29

Score3/3

Weight11.49%

1M Return2.64%

Cash-UP

Value-0.16

Score1/3

Weight1.95%

1M Return0.57%

Fixed assets turnover ratio

Value329.17

Score3/3

Weight10.60%

1M Return2.46%

Interest coverage ratio (EBIT / Interest expense) (%)

Value34.91

Score2/3

Weight10.48%

1M Return2.44%

Diluted earnings per share (YoY growth rate %)

Value-112.50

Score3/3

Weight21.90%

1M Return4.62%

Asset-MV

Value-0.55

Score0/3

Weight-1.84%

1M Return-0.57%

Net profit attributable to parent company shareholders (YoY growth rate %)

Value-98.91

Score2/3

Weight17.36%

1M Return3.66%

Current ratio

Value1.47

Score3/3

Weight10.92%

1M Return2.53%

Is CLOV undervalued or overvalued?

CLOV scores 6.06/10 on fundamentals and holds a Discounted valuation at present. Backed by its -26.33% ROE, -4.45% net margin, -11.16 P/E ratio, 3.09 P/B ratio, and -112.50% earnings growth, these metrics solidify its Outperform investment rating.